Last updated: September 4, 2026
Brilliant Blue G is a laboratory dye and experimental pharmacology compound, not an FDA-approved pharmaceutical product. Its commercial market is concentrated in research reagents, biochemical assays, neuroscience studies and preclinical drug discovery. There is no established prescription market, Orange Book listing, FDA-approved indication, publicly reported product revenue or conventional pharmaceutical exclusivity timeline for Brilliant Blue G.
What is Brilliant Blue G and how is it used?
Brilliant Blue G usually refers to Coomassie Brilliant Blue G-250, a sulfonated triphenylmethane dye identified by CAS Registry Number 6104-58-1. It is used in protein quantification, electrophoresis, histology and laboratory staining. Research literature also describes pharmacological activity involving purinergic signaling, including P2X7 receptor modulation, and experimental use in neurological and inflammatory models (National Center for Biotechnology Information [NCBI], n.d.-a).
The name creates a material commercial risk because Brilliant Blue G is often confused with Brilliant Blue FCF, also known as FD&C Blue No. 1. The two compounds have different chemical identities, regulatory histories and commercial markets.
| Attribute |
Brilliant Blue G |
Brilliant Blue FCF |
| Common identity |
Coomassie Brilliant Blue G-250 |
FD&C Blue No. 1 |
| CAS number |
6104-58-1 |
3844-45-9 |
| Primary market |
Research reagent and laboratory stain |
Food, beverage, cosmetic and pharmaceutical excipient colorant |
| FDA drug approval |
None identified |
Not an approved active pharmaceutical ingredient |
| Orange Book status |
No listed product identified |
No listed drug product as active ingredient |
| Therapeutic status |
Experimental and preclinical |
Color additive and excipient use |
| Revenue disclosure |
No standalone public revenue |
Revenue generally embedded in color-additive suppliers' portfolios |
What is the FDA regulatory status of Brilliant Blue G?
Brilliant Blue G does not have an FDA-approved drug application, approved label or established therapeutic indication. It is not listed as an active ingredient in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book (U.S. Food and Drug Administration [FDA], n.d.-a).
The FDA's color-additive framework applies to specified substances and uses. Authorization of Brilliant Blue FCF as a color additive does not establish approval for Brilliant Blue G as a drug or therapeutic agent. Companies cannot rely on Brilliant Blue FCF's food or excipient status to support a Brilliant Blue G pharmaceutical product.
A therapeutic product containing Brilliant Blue G would generally require an investigational new drug pathway, nonclinical pharmacology and toxicology, chemistry, manufacturing and controls documentation, clinical trials and a new drug application. A formulation for local or systemic administration would require separate evaluation of exposure, impurities, dose, route and safety.
| Regulatory question |
Status for Brilliant Blue G |
| FDA-approved drug |
No approved product identified |
| FDA Orange Book listing |
None identified |
| Approved therapeutic indication |
None identified |
| Approved biological product |
Not applicable |
| FDA-recognized generic reference product |
None identified |
| Established prescription exclusivity |
None |
| Established over-the-counter monograph status |
None identified |
| Clinical development pathway |
Experimental; would require standard FDA drug-development pathway |
When does Brilliant Blue G lose exclusivity?
Brilliant Blue G has no recognized pharmaceutical exclusivity period to expire. It is an old chemical compound sold by multiple laboratory suppliers, so any basic composition protection would generally be unavailable or highly vulnerable because of public disclosure and longstanding commercial use.
The relevant IP questions are narrower:
- Whether a supplier owns a valid process patent for a particular grade or manufacturing route.
- Whether a sponsor has patent claims covering a specific therapeutic use.
- Whether a formulation improves solubility, stability, tissue targeting or safety.
- Whether a delivery system combines Brilliant Blue G with a device, nanoparticle, polymer, liposome or implant.
- Whether manufacturing specifications create trade-secret protection.
Those rights would not create broad exclusivity over the chemical itself. They could protect a defined use or product configuration if the claims satisfy novelty, non-obviousness, enablement and written-description requirements.
What patents protect Brilliant Blue G?
No broad, commercially dominant pharmaceutical patent estate for Brilliant Blue G is established in the public regulatory record. Patent activity, where present, is more likely to involve therapeutic applications, combinations, formulations or manufacturing processes than the dye's basic chemical identity.
| Potential protection category |
Commercial relevance |
Likely durability |
| Basic chemical composition |
Low for an old, widely disclosed dye |
Weak or unavailable |
| Purification and manufacturing process |
Relevant to pharmaceutical-grade material |
Depends on claim scope and prior art |
| P2X7-related method of use |
Could support a defined indication |
Dependent on clinical and patent validity evidence |
| Neuroprotective or anti-inflammatory use |
Potentially relevant in preclinical development |
Vulnerable if claims are broad or obvious |
| Injectable or implantable formulation |
Could support product differentiation |
Stronger if formulation solves a documented technical problem |
| Combination therapy |
Could create narrow protection |
Dependent on clinical utility and obviousness |
| Device or delivery platform |
May create product-specific barriers |
Limited to the claimed system |
Patent searches must distinguish Brilliant Blue G from Brilliant Blue FCF, Coomassie dyes, sulfonated triphenylmethane compounds and unrelated blue dyes. A search using only the commercial name can produce both false positives and missed family members.
Are there Paragraph IV challenges involving Brilliant Blue G?
No conventional Paragraph IV challenge is expected because Brilliant Blue G has no identified FDA reference-listed drug and no Orange Book patent listing. Paragraph IV litigation applies when an abbreviated new drug application applicant certifies that a listed patent is invalid, unenforceable or will not be infringed.
There is no generic-launch pathway comparable to a branded small-molecule medicine. A company developing a therapeutic Brilliant Blue G product would likely pursue an independent new drug application rather than an abbreviated application, unless an approved reference product emerged in the future.
What formulation patents could protect Brilliant Blue G?
Formulation development would be central to any attempt to convert Brilliant Blue G from a research chemical into a pharmaceutical product. The dye's commercial laboratory use does not establish suitability for systemic administration.
Potential formulation areas include:
- Aqueous injectable solutions with controlled pH and osmolality.
- Sterile ophthalmic or intrathecal preparations.
- Sustained-release implants or depot systems.
- Liposomal or polymeric nanoparticles.
- Tissue-targeted delivery systems.
- Stabilized formulations that limit aggregation or degradation.
- Combination products with anti-inflammatory, neuroprotective or analgesic agents.
- Pharmaceutical-grade purification methods that reduce residual reagents and dye-related impurities.
A formulation patent would have greater commercial value if it linked a defined composition to improved pharmacokinetics, reduced toxicity or a clinically relevant outcome. A claim limited to routine excipients, standard sterilization or predictable concentration adjustments would face greater validity risk.
What method-of-use patents could protect Brilliant Blue G?
The strongest potential patent value would likely reside in a specific therapeutic use supported by clinical evidence. Research involving P2X7 signaling creates a possible platform for claims in inflammation, neuropathic pain, neurodegeneration or tissue injury, but preclinical mechanism alone does not create a commercial pharmaceutical franchise.
Potential method-of-use categories include:
| Use area |
Development position |
Commercial assessment |
| Neuroprotection |
Primarily experimental |
High clinical and regulatory risk |
| Neuropathic pain |
Mechanistically plausible in some studies |
Competitive field with substantial alternatives |
| Inflammation |
Possible P2X7-related application |
Requires differentiated efficacy and safety |
| Spinal cord or brain injury |
Preclinical opportunity |
Route-of-administration risk is material |
| Ocular injury or disease |
Could support local delivery |
Formulation and tolerability would control value |
| Research assay use |
Established laboratory demand |
Low pharmaceutical pricing power |
A use patent would not prevent sale of Brilliant Blue G for protein staining or research. It would need claims directed to the protected therapeutic method, dosage, patient population or formulation.
What is the market size for Brilliant Blue G?
There is no reliable public estimate for a standalone Brilliant Blue G pharmaceutical market. Supplier catalogs indicate a fragmented research-reagent market rather than a centralized branded-drug market. Sales are distributed among laboratory chemical vendors, life-science distributors and specialty reagent manufacturers.
Commercial demand comes from:
- Protein electrophoresis and staining.
- Biochemistry laboratories.
- Academic neuroscience research.
- Cell biology and receptor assays.
- Preclinical pharmacology.
- Contract research organizations.
- Teaching and diagnostic research laboratories.
Research-grade products are typically sold in milligram-to-gram quantities, while industrial or bulk dye economics can differ materially. Pricing depends on purity, certification, packaging, analytical documentation and intended use. Pharmaceutical-grade material would require a separate supply chain, including validated synthesis, impurity control, batch records, stability data and potentially sterile manufacturing.
No public company appears to report Brilliant Blue G revenue as a standalone line item. Financial exposure is therefore indirect and embedded in broader reagent, analytical chemical or life-science product portfolios.
What is the financial trajectory for Brilliant Blue G?
The financial trajectory is best characterized as stable niche reagent demand with limited evidence of pharmaceutical revenue creation.
| Period |
Commercial condition |
Financial implication |
| Historical |
Longstanding use in protein and laboratory staining |
Mature, diversified reagent demand |
| Current research market |
Continued academic and industrial use |
Recurring but fragmented sales |
| Therapeutic development |
No established approved product |
No validated pharmaceutical revenue stream |
| Near-term outlook |
Dependent on research funding and assay demand |
Moderate volatility, limited pricing power |
| Long-term upside |
Requires successful clinical development |
High potential but low probability relative to reagent base |
A successful therapeutic program could create a new value pool through patent-protected formulations or indications. That upside is not reflected in current commercial sales and should not be treated as forecast revenue without clinical, regulatory and manufacturing milestones.
The principal financial risks are development failure, systemic toxicity, inadequate exposure, weak selectivity, formulation complexity and competition from established P2X7 modulators or other anti-inflammatory and neuroprotective therapies. Research-use sales would not finance a conventional late-stage pharmaceutical program without external capital, licensing or partnership support.
Which companies are challenging or commercializing Brilliant Blue G?
The commercial field is likely populated by laboratory-supply companies rather than branded pharmaceutical competitors. Suppliers may sell Brilliant Blue G-250 under different grades, pack sizes and quality specifications. No established pharmaceutical manufacturer has been identified as marketing Brilliant Blue G as an approved therapeutic.
Competitive differentiation is based on:
- Purity and lot consistency.
- Certificate-of-analysis quality.
- Packaging and shelf life.
- Regulatory documentation.
- Distribution reach.
- Price per gram.
- Availability of related dyes and assay reagents.
No publicly established Paragraph IV challenger, biosimilar competitor or branded generic market exists for Brilliant Blue G.
Does Brilliant Blue G have biosimilar risk?
Biosimilar risk is not applicable. Brilliant Blue G is a small chemical compound, not a biological product. If a therapeutic product were approved, competition would more likely arise through an abbreviated small-molecule pathway or a separate new drug application, subject to the existence of an approved reference product and applicable FDA requirements.
What patent litigation and settlement agreements affect Brilliant Blue G?
No major public patent litigation or settlement framework is established for Brilliant Blue G as a pharmaceutical product. The absence of an Orange Book listing removes the standard litigation pattern involving listed patents, Paragraph IV notices, 30-month stays and generic-launch settlements.
Disputes could still arise over:
- Research-use patent claims.
- Process patents.
- Therapeutic method patents.
- Formulation ownership.
- Inventorship.
- Trade secrets involving pharmaceutical-grade production.
- Contract manufacturing and supply rights.
Such disputes would be project-specific rather than evidence of a mature branded-drug market.
How does Brilliant Blue G compare with Brilliant Blue FCF?
Brilliant Blue FCF has a broader industrial and consumer colorant market, while Brilliant Blue G is more closely associated with laboratory research. FCF's regulatory recognition as a color additive does not transfer to G.
| Commercial factor |
Brilliant Blue G |
Brilliant Blue FCF |
| Main demand driver |
Laboratory and research use |
Food, beverage, cosmetic and excipient use |
| Pharmaceutical active use |
Experimental |
None established |
| Market breadth |
Narrower |
Broader |
| Regulatory framework |
Chemical and research supply |
Color-additive regulations |
| Therapeutic IP opportunity |
Experimental use and formulation patents |
Limited as an active drug candidate |
| Standalone drug revenue |
None identified |
None identified |
What generic launch scenarios exist for Brilliant Blue G?
There is no current generic launch scenario. A future therapeutic product could face three broad competitive outcomes:
- A sponsor develops an approved product with method-of-use and formulation patents. Competition would depend on patent scope and regulatory exclusivity.
- A sponsor obtains approval with limited patent protection. Independent applicants could enter after applicable exclusivity and patent barriers end.
- Clinical development fails or remains niche. Commercial activity would continue mainly through research reagents.
The third scenario is the most consistent with the current public record.
Key Takeaways
- Brilliant Blue G is primarily a research dye and experimental pharmacology compound.
- It has no identified FDA-approved drug, Orange Book listing or established therapeutic exclusivity.
- No standalone pharmaceutical revenue or validated commercial forecast is available.
- Basic composition protection is unlikely to provide meaningful exclusivity for an old, widely disclosed compound.
- Commercially relevant IP would likely focus on formulations, delivery systems, manufacturing processes and narrow therapeutic uses.
- Paragraph IV litigation, biosimilar competition and generic substitution are not currently applicable.
- The established market is fragmented research-reagent demand.
- Pharmaceutical upside depends on successful clinical development, regulatory approval and defensible formulation or method-of-use patents.
- Brilliant Blue G should not be confused with Brilliant Blue FCF, a separate color additive with a broader industrial market.
FAQs
Is Brilliant Blue G the same as FD&C Blue No. 1?
No. Brilliant Blue G generally refers to Coomassie Brilliant Blue G-250, while FD&C Blue No. 1 refers to Brilliant Blue FCF. They have different CAS numbers, applications and regulatory profiles.
Can Brilliant Blue G be sold as a pharmaceutical drug?
It can be sold as a research chemical, but a therapeutic product would require appropriate FDA development and approval. Laboratory availability does not establish drug approval.
Does Brilliant Blue G have an Orange Book patent?
No Orange Book-listed Brilliant Blue G product or associated pharmaceutical patent listing has been identified.
Is Brilliant Blue G used in P2X7 drug development?
It has been studied in experimental pharmacology involving purinergic signaling, including P2X7-related research. That work does not establish clinical efficacy or an approved indication.
Is Brilliant Blue G a commercially attractive licensing asset?
Its current reagent sales do not support a conventional drug-licensing valuation. Licensing value would depend on reproducible therapeutic data, a clinically practical formulation, freedom to operate and patent claims that cover a meaningful patient population.
References
-
National Center for Biotechnology Information. (n.d.-a). PubChem compound summary: Brilliant Blue G. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Brilliant-Blue-G
-
National Center for Biotechnology Information. (n.d.-b). PubChem compound summary: Brilliant Blue FCF. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Brilliant-Blue-FCF
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.-b). Color additives and cosmetics. https://www.fda.gov/industry/color-additives
-
U.S. Food and Drug Administration. (n.d.-c). Investigational new drug application process. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
